Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “hold” rating restated by investment analysts at J P Morgan Chase & Co in a research report issued to clients and investors on Tuesday.

Several other research firms also recently issued reports on REGN. Leerink Swann reaffirmed a “positive” rating and set a $552.00 price objective (down from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $557.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Zacks Investment Research downgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Guggenheim reaffirmed a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $500.00 price objective (up from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Four analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $488.57.

Shares of Regeneron Pharmaceuticals (REGN) traded down 1.35% during mid-day trading on Tuesday, reaching $397.18. 490,698 shares of the company’s stock traded hands. The company’s 50 day moving average is $439.34 and its 200 day moving average is $459.46. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55. The company has a market cap of $42.11 billion, a P/E ratio of 39.85 and a beta of 1.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company’s revenue was up 21.2% compared to the same quarter last year. During the same period last year, the firm posted $2.82 earnings per share. On average, analysts predict that Regeneron Pharmaceuticals will post $14.94 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by J P Morgan Chase & Co” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/01/regeneron-pharmaceuticals-inc-regn-rating-reiterated-by-j-p-morgan-chase-co.html.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi acquired 166,415 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The stock was purchased at an average price of $480.93 per share, for a total transaction of $80,033,965.95. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 89,468 shares of company stock valued at $42,312,448. Company insiders own 10.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in REGN. Teachers Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Teachers Advisors LLC now owns 98,126 shares of the biopharmaceutical company’s stock valued at $38,025,000 after purchasing an additional 4,136 shares in the last quarter. Thrivent Financial For Lutherans grew its holdings in shares of Regeneron Pharmaceuticals by 6.5% in the first quarter. Thrivent Financial For Lutherans now owns 2,790 shares of the biopharmaceutical company’s stock valued at $1,081,000 after purchasing an additional 170 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Regeneron Pharmaceuticals by 2.6% in the first quarter. Dimensional Fund Advisors LP now owns 159,294 shares of the biopharmaceutical company’s stock valued at $61,725,000 after purchasing an additional 4,039 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 201.4% in the first quarter. AQR Capital Management LLC now owns 8,805 shares of the biopharmaceutical company’s stock valued at $3,412,000 after purchasing an additional 5,884 shares in the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $233,000. Hedge funds and other institutional investors own 67.57% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.